|
|
|
|
|
|
|
|
|
|
Super Quote | Detail Quote | Interactive Chart | Transaction | Related News | Related Securities | Company Information | Dividend Records | Short Sell
09939 KINTOR PHARMA-B
Nominal 
0.970 0.000 (0.000%) | 2023/12 - Final RMB(K¥) | %Chg (Compare to Final) | 2022/12 RMB(K¥) | 2021/12 RMB(K¥) | 2020/12 RMB(K¥) | 2019/12 RMB(K¥) | |
| Turnover | 0 | -- | 0 | 34,231 | 0 | 0 |
| Cost of Sales | (42,229) | -- | -- | -- | -- | -- |
| Gross Profit | (42,229) | -- | -- | -- | -- | -- |
| 2023/12 - Final RMB(K¥) | %Chg (Compare to Final) | 2022/12 RMB(K¥) | 2021/12 RMB(K¥) | 2020/12 RMB(K¥) | 2019/12 RMB(K¥) | ||
| Change in FV & Impairment on Inv. Prop. | -- | -- | -- | -- | -- | -- | |
| Change in FV & Impairment on Others | -- | -- | -- | -- | -- | -- | |
| Profit / (Loss) on Disposal | -- | -- | -- | -- | -- | -- | |
| Other Non-operating Items | -- | -- | -- | -- | -- | -- | |
| Share of Results of Asso. & JCEs | 52 | -- | (568) | 0 | 0 | 0 | |
| Profit / (Loss) before Taxation | (1,068,861) | 12.124% | (953,284) | (842,095) | (508,228) | (232,577) | |
| Taxation | 8,041 | -- | (1,085) | 0 | (73) | 0 | |
| Profit / (Loss) from Discontinued Operations | -- | -- | -- | -- | -- | -- | |
| Non-controlling Interests | 0 | -- | 0 | 0 | 0 | 0 | |
| Others | -- | -- | -- | -- | -- | -- | |
| Profit / (Loss) Attributable to Shareholders | (1,060,820) | 11.154% | (954,369) | (842,095) | (508,301) | (232,577) | |
| 2023/12 - Final RMB(K¥) | %Chg (Compare to Final) | 2022/12 RMB(K¥) | 2021/12 RMB(K¥) | 2020/12 RMB(K¥) | 2019/12 RMB(K¥) | |
| Net Finance Costs / (Income) | (3,387) | -- | 1,305 | (9,555) | (7,040) | 1,836 |
| Depreciation & Amortisation | 18,976 | 3.198% | 18,388 | 10,510 | 6,501 | 4,648 |
| Directors' Emoluments | 27,362 | 47.321% | 18,573 | 6,570 | 4,754 | 3,831 |
| 2023/12 - Final | %Chg (Compare to Final) | 2022/12 | 2021/12 | 2020/12 | 2019/12 | |
| Auditor's Opinion Status | Unqualified | -- | Unqualified | Unqualified | Unqualified | Unqualified |
Market Valuation Indicators
| 2023/12 - Final | %Chg (Compare to Final) | 2022/12 | 2021/12 | 2020/12 | 2019/12 | |
| EPS (cts) | -247.000 | -2.372% | -253.000 | -236.000 | -164.000 | -97.000 |
| DPS (cts) | 0.000 | -- | 0.000 | 0.000 | 0.000 | -- |
| Dividend Payout Ratio (%) | -- | -- | -- | -- | -- | -- |
| Cash flow per share ($) | (0.903) | -- | (2.553) | (2.950) | (1.231) | (0.953) |
| NBV per share ($) | 1.024 | -- | 3.341 | 4.270 | 4.082 | -- |
| Remarks: | Real time quote last updated: 27/12/2024 18:00 |
| Real-time basic market prices of Hong Kong securities are provided by HKEx; a Designated Website authorized by the HKEx Group to provide the Service. | |
| Profit / (Loss) Attributable to Shareholders (¥) | RMB -71,493,000 |
| %Change | -66.295% |
| EPS / (LPS) | RMB -0.170 |
| NBV Per Share (¥) | RMB 0.875 |